Weekly Digest - May 2026
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - May 2026
07 May 2026: InnoCare Pharma’s independently developed CDH17-targeted ADC innovative drug ICP B208 has been approved for clinical trials
- InnoCare Pharma has expanded its ADC pipeline after receiving National Medical Products Administration approval for clinical testing of its CDH17-targeted ADC ICP-B208, marking the company’s second internally developed ADC to enter the clinic
- ICP-B208 is designed to target CDH17-expressing tumors with a potent cytotoxic payload, with preclinical data demonstrating encouraging antitumor activity across multiple gastrointestinal cancer models
- The program enters a rapidly growing area of interest, as CDH17 is highly expressed across multiple gastrointestinal cancers and is increasingly viewed as a promising next-generation ADC target with no approved therapies currently available
- With ICP-B208 now moving into clinical evaluation, InnoCare continues to position itself among the emerging Chinese biotech players advancing next-generation ADC innovation in solid tumors
